^
    21d
    A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=41, Completed, Jacobio Pharmaceuticals Co., Ltd. | Recruiting --> Completed | N=30 --> 41
    Trial completion • Enrollment change • First-in-human
    |
    JAB-8263
    25d
    JAB-8263-1002: A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors (clinicaltrials.gov)
    P1/2, N=152, Recruiting, Jacobio Pharmaceuticals Co., Ltd. | Trial completion date: Sep 2024 --> Jul 2028 | Trial primary completion date: Jan 2024 --> Jan 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    JAB-8263
    over1year
    Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties. (PubMed, ACS Omega)
    Furthermore, JAB-2485 exhibited robust in vivo antitumor activity both as monotherapy and in combination with chemotherapies or the bromodomain inhibitor JAB-8263 in xenograft models of various cancer types. Together, these encouraging preclinical data provide a strong basis for safety and efficacy evaluations of JAB-2485 in the clinical setting.
    PK/PD data • Preclinical • Journal
    |
    AURKA (Aurora kinase A) • AURKB (Aurora Kinase B)
    |
    JAB-8263
    almost3years
    Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models. (PubMed, World J Gastrointest Oncol)
    BET could be a potential effective drug target for suppressing CRC growth, and the BET inhibitor JAB-8263 can effectively suppress c-MYC expression and exert anti-tumor activity in CRC models.
    Preclinical • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ANXA5 (Annexin A5)
    |
    MYC expression
    |
    JAB-8263